Cogent Biosciences, Inc. cotiza a 28.30 USD y tiene una capitalización bursátil de $4.9B. Datos fundamentales de la SEC EDGAR con hasta 20 años de histórico, insiders, institucionales y valoración DCF.Más empresas del sector Salud
Cogent Biosciences, Inc., a clinical-stage biotechnology company, focuses on developing precision therapies for genetically defined diseases. Its lead product candidate includes bezuclastinib (CGT9486), a selective tyrosine kinase inhibitor in Phase 3 trial designed to target mutations within the KIT receptor tyrosine …
| Periodo | 2026-11 | 2026-08 | 2026-05 | 2026-02 |
|---|---|---|---|---|
| Real | — | $-0.52 | $-0.53 | $-0.56 |
| Estimado | $-0.55 | $-0.56 | $-0.54 | $-0.51 |
| Sorpresa | — | +7.1% | +1.9% | -9.8% |
| Métrica | COGT | Mediana Sector | Δ |
|---|---|---|---|
| Gross Margin | — | 57.0% | — |
| Operating Margin | — | -38.6% | — |
| Net Margin | — | -33.6% | — |
| FCF Margin | — | -13.9% | — |
| ROE | -51.7% | -40.4% | -11.3% |
| ROA | -35.1% | -32.0% | -3.1% |
| Current Ratio | 14.23 | 2.84 | +11.39 |
| Debt / Equity | 0.35 | 0.28 | +0.07 |